Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects

Overview

The purpose of this study is to evaluate the binding of a novel tracer, [11C]TASP0410699, using Positron Emission Tomography (PET) scans with or without dosing of TS-121

Full Title of Study: “A Phase 1 Receptor Occupancy Study Using Positron Emission Tomography to Investigate Novel Ligand [11C]TASP0410699 Alone and Following Single Oral Dose Administrations of TS-121 in Healthy Adult (Male) Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2016

Interventions

  • Drug: TS-121
    • Oral
  • Drug: [11C]TASP0410699
    • Intravenous radiotracer
  • Radiation: Positron Emission Tomography (PET)
    • Imaging scanning procedure

Arms, Groups and Cohorts

  • Experimental: PART 1 (Test/Retest)
    • Dosing with [11C]TASP0410699 for PET imaging without dosing of TS-121
  • Experimental: PART 2 (PET Receptor Occupancy Study)
    • Dosing with [11C]TASP0410699 for PET imaging with dosing of TS-121

Clinical Trial Outcome Measures

Primary Measures

  • Positron emission tomography measure (receptor occupancy)
    • Time Frame: Day 1 through Day 3

Secondary Measures

  • Pharmacokinetic parameters of TS-121
    • Time Frame: Day 1 through Day 3
    • Area under the plasma concentration (AUC) from time zero to time of last measurable concentration
  • Pharmacokinetic parameters of TS-121
    • Time Frame: Day 1 through Day 3
    • Maximum concentration (Cmax)
  • Pharmacokinetic parameters of TS-121
    • Time Frame: Day 1 through Day 3
    • Time to attain cmax (Tmax)
  • Composite safety as assessed by clinical laboratory tests, 12-lead ECG, vital signs, adverse events and physical examinations
    • Time Frame: up to Day 11

Participating in This Clinical Trial

Inclusion Criteria

1. Healthy males 18 – 55 years of age (at time of initial informed consent) 2. Body weight ≥ 50 kg 3. Body Mass Index (BMI) 18 – 30 kg/m2 4. Male subjects with partners of childbearing potential must agree to use appropriate and effective measures of contraception for 90 days following drug administration Exclusion Criteria:

1. Prescription, over-the-counter or herbal medications, supplements, within 14 days before the study. 2. Clinically significant abnormal electrocardiogram, physical examination, or hematology, biochemistry, hormone, or urinalysis values at screening & baseline. 3. Significant history &/or presence of hepatic, renal, cardiovascular, hemodynamic, pulmonary, gastrointestinal, hematological, CNS, immunologic, ophthalmologic, metabolic, endocrine, or oncological disease or condition within last 5 years. 4. Current use of tobacco or tobacco-containing products, recent history of alcohol or drug abuse OR positive urine screen for alcohol or controlled substances at screening or baseline. 5. History &/or current evidence of serologic positive results for hepatitis B or C, or HIV. 6. Donation or acute loss of 450 milliliters or more of blood or plasma, within 60 days of the study. 7. Any subject who has received treatment with a non-FDA approved drug within 30 days of study screening. 8. Subjects who suffer from claustrophobia. 9. Current, past, or anticipated exposure to radiation in the workplace or participation in other research studies involving ionizing radiation that would exceed the yearly dose limits for normal subjects.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Taisho Pharmaceutical R&D Inc.
  • Collaborator
    • Yale University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Richard E. Carson, Ph.D., Principal Investigator, Yale University
    • Shoji Yasuda, Study Director, Taisho Pharmaceutical R&D Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.